EGFR and non-small cell lung carcinoma: Gefitinib is an effective selective inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), which has been approved for treating advanced non-small cell lung cancer (NSCLC) patients in the first line, showing better clinical efficacy than chemotherapy [3, 4].